74 results
Page 2 of 4
8-K
EX-10.1
yfxnxxzt
15 Jun 21
INmune Bio, Inc. Announces $15 Million Credit Facility to Purchase Xencor Option to Reduce Future Dilution
4:03pm
8-K
EX-10.2
jamksh4171qmk56
15 Jun 21
INmune Bio, Inc. Announces $15 Million Credit Facility to Purchase Xencor Option to Reduce Future Dilution
4:03pm
8-K
EX-10.4
eb69c 4wo
15 Jun 21
INmune Bio, Inc. Announces $15 Million Credit Facility to Purchase Xencor Option to Reduce Future Dilution
4:03pm
8-K
EX-10.5
qmlbih ik1vuysv
15 Jun 21
INmune Bio, Inc. Announces $15 Million Credit Facility to Purchase Xencor Option to Reduce Future Dilution
4:03pm
8-K
EX-10.1
qufilxfy qwqt7blko8
3 Jun 21
Departure of Directors or Certain Officers
4:01pm
8-K
EX-10.1
j57k5q4 45sb39wl
29 Mar 21
Entry into a Material Definitive Agreement
5:07pm
8-K
EX-10.1
65qpuuge46 rt
10 Feb 20
INmune Bio, Inc. Awarded $500,000 Grant for Development of Novel Treatment to Reprogram Innate Immune System in People Living with ALS
9:22am
8-K
EX-10.1
dna6d
27 Jan 20
Entry into a Material Definitive Agreement
5:24pm
8-K/A
EX-10.3
gbhi0v f3h
24 May 19
Entry into a Material Definitive Agreement
4:12pm
8-K
EX-10.2
c41wd53
17 May 19
Entry into a Material Definitive Agreement
2:43pm
8-K
EX-10.1
7jjp pptlr8cihume
17 May 19
Entry into a Material Definitive Agreement
2:43pm
8-K
EX-10.1
1nanplz gqizcesu
16 May 19
INmune Bio Reports First Quarter 2019 Financial Results and Provides Shareholder Update
6:06am
8-K
EX-10.2
zmjvl4lo n201z2jw5kd
16 May 19
INmune Bio Reports First Quarter 2019 Financial Results and Provides Shareholder Update
6:06am
S-1/A
EX-10.22
rcezdmhccyda93vwc
26 Sep 18
IPO registration (amended)
12:00am